Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population

TURKOVAC™ is a whole-virion inactivated COVID-19 vaccine which was developed and granted emergency use and conditional marketing authorization in December 2021 in Türkiye. The objective of this study is to assess the distribution and the severity of allergic adverse events following the administrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kara, Ateş, Coskun, Aslihan, Temel, Fehminaz, Özelci, Pervin, Topal, Selmur, Ates, İhsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958953/
https://www.ncbi.nlm.nih.gov/pubmed/36851314
http://dx.doi.org/10.3390/vaccines11020437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958953/
https://www.ncbi.nlm.nih.gov/pubmed/36851314
http://dx.doi.org/10.3390/vaccines11020437

Ejemplares similares